{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib+tablets", "query": { "intervention": "ruxolitinib tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 57, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib+tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-23T19:02:23.120Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07085039", "title": "Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castleman's Disease (CD)", "Idiopathic Multicentric Castleman's Disease" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 14, "start_date": "2025-12-18", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07085039" }, { "nct_id": "NCT05980806", "title": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Moderate Thrombocytopenia", "Mild Thrombocytopenia" ], "interventions": [ { "name": "Selinexor 60 mg", "type": "DRUG" }, { "name": "Selinexor 40 mg", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Pacritinib", "type": "DRUG" }, { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2024-04-22", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 7, "location_summary": "Duarte, California • Columbia, Maryland • New York, New York + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Columbia", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05980806" }, { "nct_id": "NCT04041050", "title": "A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Navitoclax", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-11-08", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-02-14", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 12, "location_summary": "Duarte, California • Fullerton, California • La Jolla, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04041050" }, { "nct_id": "NCT06555081", "title": "A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Ruxolitinib IR", "type": "DRUG" }, { "name": "Ruxolitinib XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 168, "start_date": "2024-09-25", "completion_date": "2024-11-07", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06555081" }, { "nct_id": "NCT01969838", "title": "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Momelotinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo to match momelotinib", "type": "DRUG" }, { "name": "Placebo to match ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sierra Oncology LLC - a GSK company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 432, "start_date": "2013-12-06", "completion_date": "2019-05-02", "has_results": true, "last_update_posted_date": "2023-05-12", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Escondido, California • Stanford, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01969838" }, { "nct_id": "NCT01790295", "title": "Ruxolitinib Prior to Transplant in Patients With Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post Polycythemia Vera Myelofibrosis", "Post Essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2013-11", "completion_date": "2017-10-26", "has_results": true, "last_update_posted_date": "2019-03-20", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Westwood, Kansas + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01790295" }, { "nct_id": "NCT01730755", "title": "Ruxolitinib for Chuvash Polycythemia", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Erythrocytosis, Familial, 2" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2018-05-14", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730755" }, { "nct_id": "NCT04640025", "title": "A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Postlung Transplant (Bronchiolitis Obliterans)", "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-03-10", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 8, "location_summary": "Duarte, California • Aurora, Colorado • Fort Wayne, Indiana + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640025" }, { "nct_id": "NCT02120417", "title": "A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 149, "start_date": "2014-05", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Sedona, Arizona + 77 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120417" }, { "nct_id": "NCT06615050", "title": "A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft-versus-host Disease (GVHD)" ], "interventions": [ { "name": "Tacrolimus (Tac)", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Ruxolitinib (Rux)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 572, "start_date": "2025-04-02", "completion_date": "2031-01-17", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-09-23T19:02:23.120Z", "location_count": 30, "location_summary": "Palo Alto, California • San Francisco, California • Miami, Florida + 23 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06615050" } ] }